Join CARB-X Executive Director Kevin Outterson at #GAMRIC2026, where he will highlight key milestones and CARB-X's contributions to revitalizing the antibacterial pipeline, and share CARB-X’s vision for the next 10 years. #IDSky 🧪 📅 Sept. 23  ⏰ 10:30 AM – 10:45 AM WEST   🔗 bit.ly/4kE2oKV 

Join CARB-X Alliance Director Betsy Wonderly Trainor at the Next Generation Dx Summit, where she will examine challenges and opportunities in ensuring appropriate use and payment mechanisms to support the successful market entry of new products to address AMR. #IDSky #NGDx 🧪 🔗 bit.ly/4x5B1OZ

New in The Lancet Microbe: CARB-X Executive Director Kevin Outterson co-authored a report on the 2025 workshop convened by the authors in Lagos to help inform the development of the Independent Panel for Evidence for Action Against AMR (IPEA). #IDSky 🧪 🔗 bit.ly/4qlLdk8

A new publication defines a Target Product Profile for new antimicrobials to treat severe bacterial diarrheal disease in children under 5 in LMICs. This is the outcome of a symposium hosted by CARB-X and GNA NOW in 2024 in Porto, Portugal. #IDSky #PedsSky 🧪 🔗 bit.ly/460sfWF

A recent Nature Portfolio publication highlights India’s growing role in AMR R&D and the importance of pairing innovation with patient access. CARB-X is proud to support the development of new therapies from Bugworks and GangaGen, which were featured in the article. #IDSky 🧪 🔗 bit.ly/4hSxT4m

New research from Blacksmith Medicines, supported by CARB-X, highlights a novel class of nonhydroxamate LpxC inhibitors. CARB-X provided $7.2 million in funding and customized support from 2018-2022, advancing this program from lead optimization to preclinical development. #IDSky 🧪 🔗 bit.ly/4q0lEVj

We thank the @senatefinance.bsky.social Subcommittee on Health Care for the thoughtful bipartisan discussion yesterday on antibiotic market failure and the solutions needed to ensure lifesaving antibacterial products continue to be developed and available for patients. #PoliSky 🎥 bit.ly/45D0AuM

CARB-X Executive Director Kevin Outterson will testify today as a witness at a Senate Finance Committee Subcommittee on Health Care Hearing. Antibiotics are essential healthcare infrastructure, yet they remain undervalued and underinvested in. #PoliSky 🎥 bit.ly/45D0AuM

Drug-resistant infections are a global challenge. GAMRIC brings together the people developing the solutions. Join the #AMR community in Lisbon this September for three days of discussion, collaboration and new ideas. Register today 👉 gamric.org

📘 New publication! As part of a CARB-X Portfolio Acceleration Tool, a new publication in Clinical Infectious Diseases provides a framework for superiority clinical trials to demonstrate the clinical value of nontraditional antibacterial agents. #IDSky 🧪 🔗 bit.ly/49CR0dU

Congratulations to Trellis Bioscience on its $9M Series C for a Phase 2 trial for TRL1068, a monoclonal antibody treatment for chronic PJI. CARB-X provided $8.9M in funding from 2019-2024, advancing TRL1068 from preclinical development through Phase 1. #IDSky 🧪 🔗 bit.ly/45d1o9v 🩺 bit.ly/4fb4ctE

Congratulations to CARB-X product developer Zeteo Tech, winner of the ADLM Immunology & Infectious Disease Division Abstract Award in Microbiology! Selected from more than 800 submissions, the abstract will be featured at ADLM on July 28. #IDSky 🧪 🔗 Register: bit.ly/4aUEZ4c

📢 LAST CHANCE to submit an abstract to #GAMRIC! Late-breaking abstract submission for #GAMRIC2026 closes tomorrow, July 22 at 12pm CEST. Submit your work before the deadline to be considered. #IDSky 🧪 🔗 Submit now: bit.ly/4dwyHIl

ESCMID@escmid.bsky.social · last mo.

Last chance to submit your late breaker abstracts to #GAMRIC2026! Put on the finishing touches and submit your work to be presented during the conference and interact with innovators in #AMR. https://www.gamric.org/programme/abstracts/ LifeArc CARB-X Global Antibiotic R&D Partnership (GARDP)

CARB-X is proud to be the push incentive partner for NeoTest, a new @cgdev.org initiative that aims to accelerate the development, commercialization, and adoption of rapid diagnostics for neonatal sepsis in LMICs. #IDSky 🧪 🔗

Have you registered for #ICID2026? CARB-X is proud to support by sponsoring attendance for researchers from LMICs. CARB-X Chief of R&D Richard Alm is making a presentation at this year’s event. Early registration for the congress ends on July 30 – register now! #IDSky 🧪 🔗 bit.ly/3RpMXM2

CARB-X today announced that Dr. Richard Alm has been appointed Chief of R&D. His scientific leadership and expertise will play a key role in advancing CARB-X's mission of accelerating antibacterial innovation from early development to clinical evaluation. #IDSky 🧪 🔗

CARB-X announces Dr. Richard Alm as next Chief of Research & Development - Carb-X

Dr. Alm to lead CARB-X R&D strategy to accelerate the development of life-saving antibacterial products  (BOSTON: July 15, 2026) – Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) today announced that Richard […]

bit.ly

📢 #GAMRIC2026 early registration ends tomorrow! Last chance to register before prices increase. Secure your spot among experts from around the world discussing the future of AMR R&D, economics and policies. CARB-X staff are contributing to multiple sessions. #IDSky 🧪 🔗 bit.ly/4kE2oKV

ESCMID@escmid.bsky.social · last mo.

Early registration for #GAMRIC2026 ends tomorrow! Don't get stuck paying extra to attend this key meeting where innovators come together to discuss the challenges of #AMR drug development and how to address them. https://www.gamric.org/ LifeArc CARB-X Global Antibiotic R&D Partnership (GARDP)

#GAMRIC2026 is now accepting late-breaking abstracts! Eligible topics are listed at the link below. Submit by July 22, 2026, to be considered to present your work to a global audience working to address AMR. #IDSky 🧪 🔗 Submit here: bit.ly/4dwyHIl

ESCMID@escmid.bsky.social · 2mo ago

Late breaker abstract submission is now open for #GAMRIC2026! Learn more and submit before the deadline on 22 July: https://www.gamric.org/programme/abstracts/ Be sure to register before the early registration deadline next week on 15 July! LifeArc CARB-X Global Antibiotic R&D Partnership (GARDP)

‼️New research in Health Affairs Scholar finds CARB-X-supported projects are nearly 5x more likely to reach clinical development than comparable projects that did not receive CARB-X funding. The study is the first independent, peer-reviewed evaluation of antibacterial incentives. 🔗 bit.ly/3TlmL5J

Developing innovative rapid diagnostic solutions for Antimicrobial Resistance (AMR)? 🚀 Our Rapid Diagnostics Open Call for AMR is now open! Submit your Expression of Interest at 📋 forms.office.com/r/rt77z5X4fD before 16 August 2026! 🗓️ Find out more at ad-id.co/dt

Congratulations to SNIPR, part of REPhRAME, which received €15M from the European Commission to evaluate the combination of phage therapy and gut microbiome restoration to prevent recurrent UTIs. CARB-X-supported SNIPR001 will be the first step of the treatment strategy. #IDSky 🧪 🔗 bit.ly/4vBvA9P

CARB-X Executive Director Kevin Outterson joined global health experts calling on France to make AMR a strategic health security priority during its G7 presidential year. In Le Monde, they outline four priorities to drive action and innovation. #IDSky 🧪 🔗 bit.ly/4vc44zL 🔗 bit.ly/3SDzPDj

Have you registered for #GAMRIC2026? GAMRIC covers the full spectrum of AMR product development, including scientific, regulatory, policy, and commercial challenges. Register before July 15 early registration deadline and join the global community working to tackle AMR. #IDSky 🧪 🔗 bit.ly/4kE2oKV

ESCMID@escmid.bsky.social · 2mo ago

The #AMR community understand that they need to discuss a wide range of issues and #GAMRIC2026 is the place to do that. https://youtu.be/xI3mOPGvJVs Early registration deadline on 15 July! https://www.gamric.org/registration-travel-grants/ LifeArc CARB-X Global Antibiotic R&D Partnership (GARDP)

In a PharmaVoice article on the rise of NDM-CRE, CARB-X Executive Director Kevin Outterson explains the antibacterial pipeline requires infrastructure-level investment. CARB-X has invested $75M+ in products targeting CRE infections, but more work must be done. #IDSky 🧪 🔗 bit.ly/4gNkr10

CARB-X welcomes FDA approval of Utebzi, the first oral carbapenem approved in the US which may reduce the need for IV therapy. BARDA supported its development for 10+ years, underscoring the sustained investment and collaboration needed to develop innovative antimicrobials. #IDSky 🧪 🔗 bit.ly/4eivk9K

CARB-X is pleased to see Macro Biologics’ Phase 1 trial of Amicidin-β has commenced, a trial co-funded by CARB-X. Since 2017, CARB-X has supported Amicidin-β and helped advance it from preclinical development to Phase 1. We look forward to the progression of this study. #IDSky 🧪 🔗 bit.ly/4eiXqjW

AMR is a global threat, and the response must be global too. CARB-X Investor Day connects product developers, funders, and industry leaders to create opportunities for partnerships and investments that help advance the next generation of innovative antibacterial products. #IDSky 🧪

Check out the preliminary program for #GAMRIC2026, which will bring together global experts for high-level discussions on the future of AMR R&D and innovation. CARB-X team members are chairing and speaking in multiple sessions. #IDSky 🧪 📘 Program: bit.ly/4dwyHIl 🔗 Registration: bit.ly/4kE2oKV

ESCMID@escmid.bsky.social · 3mo ago

📢 Join us in Lisbon for the 2nd Global AMR Innovators Conference (GAMRIC), 22–24 September 2026! Explore the preliminary programme and secure your place before tickets sell out. Early registration closes on 15 July, after which registration fees will increase. 🔗 https://ow.ly/EaAm50Z6E9N

CARB-X welcomes FDA approval of Zaynich for cUTI patients. This new tool to treat MDR infections demonstrates that breakthrough innovation can emerge from diverse ecosystems around the world – a reminder that addressing AMR requires supporting innovators wherever they are. #IDSky 🔗

How Wockhardt Created India’s First FDA-Approved Novel Antibiotic

For decades, India excelled at making medicines invented elsewhere. With Zaynich, Wockhardt has become the first Indian pharma company to discover, develop, and own an FDA-approved drug

bit.ly

CARB-X Alliance Director Elizabeth Amiott will discuss navigating diagnostic product development, including translational gaps and oversights, at the @advance-id.bsky.social webinar. ADVANCE-ID is holding an open call for rapid Dx targeting AMR. #IDSky 🧪 📅 June 23 ⏰ 6 – 7PM SGT 🔗 bit.ly/4eukg8r

ADVANcing Clinical Evidence in Infectious Diseases (ADVANCE-ID)@advance-id.bsky.social · 3mo ago

Developing an affordable AMR rapid diagnostic? Join our webinar on 23 Jun 2026, 6–7 PM SGT. Learn what makes a diagnostic clinically useful, common development gaps, regulatory considerations in Asia, and details of our upcoming open call. Register: ad-id.co/3Slr0xF #AMR @carb-x.bsky.social